MERCK KGAA |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 165.1 EUR | +4.28% |
|
+7.85% | +15.37% |
| 01:24pm | UBS rates Merck KGaA a 'Buy' - Target 186 euros | DP |
| 10:44am | MERCK KGAA : UBS maintains a Buy rating | ZD |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 21.25B 23.03B | Sales 2025 * | 22.49B 24.36B | Capitalization | 68.83B 74.56B |
|---|---|---|---|---|---|
| Net income 2024 * | 2.94B 3.19B | Net income 2025 * | 3.45B 3.73B | EV / Sales 2024 * | 3.55 x |
| Net Debt 2024 * | 6.73B 7.29B | Net Debt 2025 * | 5.01B 5.43B | EV / Sales 2025 * | 3.28 x |
| P/E ratio 2024 * |
23.1
x | P/E ratio 2025 * |
19.6
x | Employees | 62,908 |
| Yield 2024 * |
1.45% | Yield 2025 * |
1.53% | Free-Float | 29.71% |
More Fundamentals
* Assessed data
More news
Latest transcript on Merck KGaA
More press releases
More news
| 1 day | +4.79% | ||
| 1 week | +7.20% | ||
| Current month | +10.94% | ||
| 1 month | +8.57% | ||
| 3 months | +6.30% | ||
| 6 months | +6.51% | ||
| Current year | +14.68% |
1 week
153.35
165.65
1 month
142.70165.65
Current year
140.50165.65
1 year
134.30172.40
3 years
134.30231.50
5 years
76.22231.50
10 years
61.05231.50
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 62 | 20-07-12 | |
Marcus Kuhnert
DFI | Director of Finance/CFO | 56 | 14-07-31 |
| Director of Finance/CFO | 53 | 19-04-25 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Christian Raabe
BRD | Director/Board Member | - | - |
Jürgen Glaser
BRD | Director/Board Member | 61 | 12-04-30 |
Gabriele Eismann
BRD | Director/Board Member | 62 | 90-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 2.34% | 2 M€ | +13.56% | - | |
| 2.01% | 0 M€ | 0.00% | - | |
| 1.80% | 962 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-15 | 166.2 | +5.02% | 354 197 |
| 24-05-14 | 158.3 | +2.46% | 298,795 |
| 24-05-13 | 154.5 | -0.64% | 235,637 |
| 24-05-10 | 155.5 | -0.13% | 225,741 |
| 24-05-09 | 155.7 | +1.01% | 156,563 |
Delayed Quote Xetra, May 15, 2024 at 09:56 am EDT
More quotes
Merck KGaA is one of the world's leading pharmaceutical and chemical groups. Net sales break down by family of products as follows:
- solutions and products for scientific and biotechnological research (44.2%);
- pharmaceutical products (38.4%): prescription drugs for the treatment of diabetes, cancer, multiple sclerosis, infertility, cardiovascular disease, central nervous system disorders, inflammatory disorders, etc.;
- performance materials for the electronics industry (17.4%): semiconductor materials, liquid crystals, pigments and additives, carbon-based organic materials, etc.
Net sales are distributed geographically as follows: Germany (4.8%), Europe (24%), China (12.9%), Asia/Pacific (20.1%), the United States (26.8%), North America (1.6%), Latin America (6.3%), Middle East and Africa (3.5%).
Sector
Pharmaceuticals
Calendar
01:00am
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A
Sell
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
158.3
EUR
Average target price
179.8
EUR
Spread / Average Target
+13.59%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +14.68% | 74.45B | |
| +11.35% | 9.18B | |
| +60.16% | 5.03B | |
| -12.85% | 5.02B | |
| +1.60% | 3.82B | |
| -19.20% | 2.41B | |
| +18.31% | 2.39B | |
| -27.46% | 2.27B | |
| +24.62% | 2.26B | |
| -0.50% | 1.64B |
- Stock Market
- Equities
- MRK Stock